Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma

Background The advent of immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC), nevertheless, the benefit of treatment is confined to a limited proportion of patients. Therefore, the identification of predictive biomarkers for r...

Full description

Bibliographic Details
Main Authors: Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Sonia Simonetti, Michele Iuliani, Marco Stellato, Silvia Cavaliere, Francesco Pantano
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/9/e005136.full

Internet

https://jitc.bmj.com/content/10/9/e005136.full

Similar Items